【正文】 2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 37 在真實世界研究中，持續(xù)一致的低支架血栓發(fā)生率 COMPARE II1 (n=1,670) vs. Nobori RESOLUTE All Comers2 (n=2,292) vs. Endeavor Resolute SPIRIT IV4 (n=3,687) vs. Taxus SORT OUT3 (n=2,774) vs. Cypher LESSON6 (n=2,684) vs. Cypher COMPARE7 (n=1,800) vs. Taxus RESOLUTE All Comers5 (n=2,292) vs. Endeavor Resolute % % % % % % % % % % % % % % p= p= p= p= p= p= p= XIENCE Competitor ARC 確定的支架血栓 (%) Source: 1. Smits, PCR 2020. , PCR 2020. , TCT 2020. 4. Stone, TCT 2020. , PCR 2020. , ESC 2020. , TCT 2020. Results from clinical trials are not directly parable. Information provided for educational purposes. Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only, and not intended for physicians from France, Japan or the United States. 169。2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 35 1 and 2 Year Definite Stent Thrombosis Rate Pooled Odds Ratio* Palmerini et al. The Lancet. March 23, 2020 DOI:(12)603249 * An odds ratio is a method of paring whether the probability of an event is the same between two groups Xience支架血栓發(fā)生率顯著低于所有對照產(chǎn)品 支架血栓網(wǎng)絡薈萃分析 XIENCE是唯一一個術后 2年支架血栓發(fā)生率低于 BMS的 DES Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only, and not intended for physicians from France, Japan or the United States. 169。這 個研究 帶 來的 發(fā)現(xiàn) 可能會 讓這 些人停下來。2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 33 支架血栓網(wǎng)絡薈萃分析 XIENCE是市場上最安全的支架 “目前 發(fā)現(xiàn) CoCrEES (XIENCE)較 BMS有更低的支架血栓 發(fā) 生率，如果在將來的研究中得到 進 一步 證實 ，將會 帶 來治 療 模式的巨大 轉變 。2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 31 0 . 00 . 51 . 01 . 52 . 0X I E N C E V M U L T I L I N K V I S I O NIncidence of ARC Def ST (%)p= % % n=751 Sources: 1M. Sabate, EXAMINATION 1Year Presentation. ESC 2020. 2W. Wijns. EXAMINATION Discussant Presentation. ESC 2020. Investigator Sponsored Study 1年 ARC 定義確定的支架血栓 1 n=747 “醫(yī)生通過使用新型的 DES，尤其是這個特定品牌的 DES，可以減少在 STEMI患者中使用 DES時對早期安全性的擔憂 .” – Dr. William Wijns EXAMINATION Discussant, ESC 20202 74% 降低 EXAMINATION 研究 XIENCE的安全性優(yōu)于 BMS Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only, and not intended for physicians from France, Japan or the United States. 169。377:124147. Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only, and not intended for physicians from France, Japan or the United States. 169。 % Endeavor Resolute。 % Endeavor Resolute。2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 27 RESOLUTE All Comers 研究 3年 結 果 ? 由美敦力 資 助的獨立的無 篩選 患者研究 ? 2,292 名患者 1:1 入 組 XIENCE V及 Resolute ? 比 較 XIENCE 與 Resolute最大的RCT研究 Source: Windecker S, PCR 2020 雙 聯(lián) 抗血小板治 療 1年 3年 XIENCE V % % Endeavor Resolute % % Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only, and not intended for physicians from France, Japan or the United States. 169。2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 25 COMPARE研究 : 隨訪 3 年支架血栓發(fā)生率 COMPARE: 支架血栓 – 3年 (ARC 確定的 ) 單中心 , 1,800例患者 ISS研究， 1:1 隨機入組 XIENCE (n=897) vs. Taxus Liberte (n=903) Source: Smits, P. Compare 3 Year Results. TCT 2020 p= (logrank test) 69% 累計事件發(fā)生率 術后時間（天） Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only, and not intended for physicians from France, Japan or the United States. 169。 377:124147。2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 23 內容 ? 臨 床使用 DAPT的 難題 ? XIENCE DAPT中斷 /停用數(shù)據(jù) ? 不同 DES的安全性表現(xiàn) Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only, and not intended for physicians from France, Japan or the United States. 169。2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 21 復雜的真實世界患者群 術后兩年低支架血栓發(fā)生率 支架血栓 ARC 確定